Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)

6 Months Ended

Jun. 30, 2025

Earnings Per Share [Abstract]

Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2025 and 2024, respectively (in thousands, except share and per share amounts):


		Three Months Ended June 30,								Six Months Ended June 30,
		2025				2024				2025				2024
Net loss attributable to Adaptive Biotechnologies Corporation		$	(25,614	)		$	(46,222	)		$	(55,466	)		$	(93,729	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted			152,082,284				147,414,095				150,646,632				146,600,811
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		$	(0.17	)		$	(0.31	)		$	(0.37	)		$	(0.64	)

Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2025 and 2024, respectively, as they had an anti-dilutive effect:


		Three Months Ended June 30,								Six Months Ended June 30,
		2025				2024				2025				2024
Stock options outstanding			11,622,872				13,055,050				11,794,753				13,070,461
Nonvested restricted stock units outstanding			11,722,493				11,174,598				11,163,655				10,757,897
Nonvested performance-based restricted stock units outstanding			124,976				—				75,262				—
Maximum nonvested market-based restricted stock units outstanding eligible to be earned			5,356,880				3,771,579				4,836,972				3,159,668
Total			28,827,221				28,001,227				27,870,642				26,988,026